Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

19.0%

71 terminated/withdrawn out of 374 trials

Success Rate

72.8%

-13.7% vs industry average

Late-Stage Pipeline

10%

39 trials in Phase 3/4

Results Transparency

49%

94 of 190 completed trials have results

Key Signals

42 recruiting94 with results54 terminated17 withdrawn

Enrollment Performance

Analytics

N/A

140(44.7%)

Phase 2

82(26.2%)

Phase 1

48(15.3%)

Phase 4

21(6.7%)

Phase 3

18(5.8%)

Early Phase 1

4(1.3%)

313Total

N/A(140)

Phase 2(82)

Phase 1(48)

Phase 4(21)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (374)

Showing 20 of 374 trials

NCT05671419Not ApplicableRecruiting

Mindful Self-Compassion for Anxiety Disorders and Depression

Role: lead

NCT05896852Not ApplicableCompleted

Healthy Lifestyles: A Home Based Physical Activity Intervention in Persons Living With HIV

Role: lead

NCT02947893Phase 2Completed

Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease

Role: lead

NCT02190253Completed

Seroprevalence of Hepatitis E in People With an Organ Transplant

Role: collaborator

NCT07540000Phase 4Not Yet Recruiting

The INTERvening for LUNG Health Trial

Role: collaborator

NCT03888222Phase 2Completed

Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies

Role: lead

NCT06049888Not ApplicableRecruiting

Does Social Media Impact Adolescent Mental Health?

Role: lead

NCT06960993Not ApplicableRecruiting

Mosaic Trial for Stem Cell Transplant Recipients

Role: collaborator

NCT04600973Not ApplicableActive Not Recruiting

Improving Implementation of Evidence-based Approaches and Surveillance to Prevent Bacterial Transmission and Infection

Role: collaborator

NCT06015724Phase 2Active Not Recruiting

Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer

Role: lead

NCT06227546Phase 2Active Not Recruiting

MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer

Role: lead

NCT07645326Phase 2Not Yet Recruiting

RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Role: lead

NCT06295250Not ApplicableRecruiting

ASHA Bangladesh--An Integrated Intervention to Address Poverty and Depression

Role: collaborator

NCT06439979Not ApplicableRecruiting

Rural Adult and Youth Sun Protection Study

Role: collaborator

NCT04002674Phase 2Completed

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies

Role: lead

NCT02954978Phase 2Completed

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease

Role: lead

NCT07644598Phase 2Not Yet Recruiting

MRI-based Focal Intraprostatic Simultaneous Integrated Boost (SIB) Intensification With De-escalated Adaptive-risk SBRT for Patients With Low to Intermediate Risk Prostate Cancer

Role: lead

NCT06449313Phase 2Recruiting

Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement

Role: lead

NCT05827055Phase 2Active Not Recruiting

Proglumide and Chemotherapy for Metastatic Pancreatic Cancer

Role: lead

NCT07635329Not ApplicableRecruiting

Home-based Vision Rehabilitation Guided by Brain Imaging

Role: lead